These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 24618665)

  • 1. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
    Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
    Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
    Maréchal R; Van Laethem JL
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
    Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
    Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
    Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
    PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
    Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
    Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
    Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
    Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HuR's role in gemcitabine efficacy: an exception or opportunity?
    Brody JR; Gonye GE
    Wiley Interdiscip Rev RNA; 2011; 2(3):435-44. PubMed ID: 21957028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
    Pineda DM; Rittenhouse DW; Valley CC; Cozzitorto JA; Burkhart RA; Leiby B; Winter JM; Weber MC; Londin ER; Rigoutsos I; Yeo CJ; Gorospe M; Witkiewicz AK; Sachs JN; Brody JR
    Cancer Biol Ther; 2012 Aug; 13(10):946-55. PubMed ID: 22785201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
    Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Salmon I; Devière J; Van Laethem JL
    Cancer; 2010 Nov; 116(22):5200-6. PubMed ID: 20669326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
    Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
    Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
    Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
    Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
    Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.